🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Customs group to fight $200 bln bogus drug industry

Published 06/10/2010, 06:00 PM

* WCO members to sign accord to fight fake drugs

* More fake than real drugs on market, official says

* Counterfeit drugs now a $200 billion-a-year industry

By John Irish

PARIS, June 10 (Reuters) - Counterfeit drugs have become a $200-billion-a-year industry and the 176-nation World Customs Organisation (WCO) will sign a declaration later this month to fight the scourge, an official said on Thursday.

Fake or substandard versions of medicines are often hidden in cargoes sent on circuitous routes to mask their country of origin. "We have more fakes than real drugs in the market," said Christophe Zimmermann, the WCO's anti-counterfeiting and piracy coordinator. "In 2007-2008 alone, it rose 596 percent."

Pharmacies and back street merchants in Africa sell fake medicines at rock-bottom prices.

The World Trade Organisation says fake anti-malaria drugs kill 100,000 Africans a year and the black market deprives governments of 2.5-5 percent of their revenue.

The Brussels-based WCO represents customs operations globally and has joined with former French president's Jacques Chirac's foundation to raise awareness at upper echelons to curtail the illicit industry.

Spurred by Chirac's foundation, 176 national customs chiefs will sign a declaration on June 24 to ban the making and marketing of counterfeit drugs, Zimmermann told Reuters.

Fake medicines often contain the wrong or toxic ingredients and pose a growing health threat worldwide, especially in poor countries where drugs are sold to treat conditions such as malaria, tuberculosis and HIV.

"If these subjects are not dealt with and strong action not taken, they will be a source of conflict," said Catherine Joubert, director general of the Fondation Chirac, adding that so far 30 groups had signed the declaration.

Getting the WCO's 176 members on board will lend legitimacy to proposals to revamp obsolete legislation and improve coordination between enforcement agencies, Zimmermann said.

Western Europeans spend an estimated 10.5 billion euros ($14.3 billion) a year on illicitly sourced medicines, according to a Pfizer-sponsored survey published in February.

In a sign Europe is taking the issue seriously too, justice ministers on the Council of Europe are set to ratify a convention on counterfeit medicines in Istanbul this November.

(Editing by Mark Heinrich)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.